SCHEMBL7070050

SCHEMBL7070050

C=C(N)C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10622154 0.78
SCHEMBL14627459 0.78
SCHEMBL17084640 0.78
SCHEMBL19928069 0.78
SCHEMBL22567268 0.78
SCHEMBL24168439 0.75
SCHEMBL21162907 0.75
SCHEMBL12635436 0.75
SCHEMBL18793254 0.75
SCHEMBL25014906 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108369907-B Liquid composition and method for surface treatment of semiconductor substrate using same 三菱瓦斯化学株式会社 2022-09-20 CN claimed
CN-118344372-A Substituted straight-chain spiro derivatives 詹森药业有限公司 2024-07-16 CN disclosed
CN-118255773-A Substituted straight-chain spiro derivatives 詹森药业有限公司 2024-06-28 CN disclosed
CN-118255774-A Substituted straight-chain spiro derivatives 詹森药业有限公司 2024-06-28 CN disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 US disclosed
US-11780823-B2 Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors BIOSPLICE THERAPEUTICS, INC. (US) 2023-10-10 US disclosed
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed
US-11731986-B2 Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof Sanford Burnham Prebys Medical Discovery Institute (US) 2023-08-22 US disclosed
US-11707457-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-07-25 US disclosed
WO-2003062257-A1 DEAZAPURINE NUCLEOSIDE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS RIBAPHARM INC. (US) 2003-07-31 WO disclosed
WO-2003051896-A1 CYTIDINE LIBRARIES AND COMPOUNDS SYNTHESIZED BY SOLID-PHASE COMBINATORIAL STRATEGIES RIBAPHARM INC. (US) 2003-06-26 WO disclosed
WO-2003051897-A1 NUCLEOSIDE ANALOG LIBRARIES AND COMPOUNDS RIBAPHARM INC. (US) 2003-06-26 WO disclosed
WO-2003051898-A1 UNUSUAL NUCLEOSIDE LIBRARIES, COMPOUNDS, AND PREFERRED USES AS ANTIVIRAL AND ANTICANCER AGENTS RIBAPHARM INC. (US) 2003-06-26 WO disclosed
WO-2003051881-A1 SUBSTITUTED PURINE NUCLEOSIDE LIBRARIES AND COMPOUNDS BY SOLID-PHASE COMBINATORIAL STRATEGIES RIBAPHARM INC. (US) 2003-06-26 WO disclosed
WO-2002078714-A1 FORMULATIONS WHICH ARE RESISTANT TO GASTRIC JUICE AND ARE USED TO APPLY ANTI-INFECTIVE COMPOUNDS INHIBITING THE 2-C-METHYLERYTHROSE-4 METABOLIC PATHWAY, AND THE SALTS AND ESTERS OF THE SAME JOMAA PHARMAKA GMBH (DE) 2002-10-10 WO disclosed
EP-1100510-A2 COMBINED PREPARATION OF ANTI-INFECTIOUSLY ACTIVE COMPOUNDS WHICH INHIBIT THE 2-C-METHYLERYTHROSE-4 METABOLIC PATHWAY, AND INHIBITORS OF LIPID METABOLISM Jomaa, Hassan (DE) 2001-05-23 EP disclosed
WO-1999066875-A2 COMBINED PREPARATION OF ANTI-INFECTIOUSLY ACTIVE COMPOUNDS WHICH INHIBIT THE 2-C-METHYLERYTHROSE-4 METABOLIC PATHWAY, AND INHIBITORS OF LIPID METABOLISM JOMAA HASSAN (DE) 1999-12-29 WO disclosed
EP-0613341-A1 NOVEL HERBICIDALLY-ACTIVE FATTY ACID SALTS Mycogen Corporation (US) 1994-09-07 EP disclosed
WO-1993009669-A1 NOVEL HERBICIDALLY-ACTIVE FATTY ACID SALTS MYCOGEN CORPORATION (US) 1993-05-27 WO disclosed